Attention Deficit Hyperactivity Disorder: VYVANSE is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
Long-term use: Pharmacological treatment of ADHD may be required for prolonged periods. The benefit of maintaining child and adolescent patients (6-17 years) and adult patients (18-55 years) with ADHD in treatment with VYVANSE in doses of 30, 50 and 70 mg / day was demonstrated in controlled and randomized trials. of withdrawal (see Pharmacodynamic properties). The doctor who decides to use VYVANSE for a long time should periodically reevaluate the long-term usefulness of the medicine for the individual patient.
Binge Eating Disorder: VYVANSE is indicated for the treatment of moderate or severe binge eating disorder in adults.
Lisdexamfetamine is not indicated or recommended as a weight loss product.